Human cytomegalovirus comprising exogenous antigens

Patent metadata

Field	Value
Publication number	US-10995121-B2
Application number	US-201916545561-A
Country	US
Kind code	B2
Filing date	Aug 20, 2019
Priority date	Jul 16, 2014
Publication date	May 4, 2021
Grant date	May 4, 2021

Abstract

Human cytomegalovirus vectors comprising heterologous antigens are disclosed. The vectors derived from the TR strain, are ganciclovir-sensitive, include active US2, US3, US6, US7 and UL131A genes, and have a deleterious or inactivating mutation in the UL82 gene preventing the expression of pp71.

First claim

The invention claimed is:

1. A recombinant human cytomegalovirus (HCMV) comprising:
(1) a first nucleic acid encoding at least one heterologous antigen;
(2) an inactivating mutation in the UL78 gene; and
(3) active US2, US3, US6, US7, UL97, and UL131A genes;
wherein the recombinant HCMV is a genetically modified TR strain of HCMV; and
the recombinant HCMV is ganciclovir-sensitive.

2. The recombinant HCMV of claim 1 , wherein the UL97 gene is derived from the AD169 strain of HCMV.

3. The recombinant HCMV of claim 1 , wherein the active US2, US3, US6, and US7 genes are derived from the AD169 strain of HCMV.

4. The recombinant HCMV of claim 1 , wherein expression of the at least one heterologous antigen is driven by the UL7 promoter, the UL45 promoter, the UL78 promoter, or the US13 promoter.

5. The recombinant HCMV of claim 1 , wherein the inactivating mutation in the UL78 gene is a deletion of all or part of the UL78 gene.

6. The recombinant HCMV of claim 5 , wherein the at least one heterologous antigen replaces all or part of the UL78 gene.

7. The recombinant HCMV of claim 6 , wherein expression of the at least one heterologous antigen replacing all or part of the UL78 gene is driven by the UL78 promoter.

8. The recombinant HCMV of claim 1 , further comprising an inactivating mutation in a HCMV gene selected from the group consisting of: UL7, UL38, UL45, and US13.

9. The recombinant HCMV of claim 8 , wherein the inactivating mutation in the UL7, UL38, UL45, or US13 gene is a deletion of all or part of the UL7, UL38, UL45, or US13 gene.

10. The recombinant HCMV of claim 9 , wherein the at least one heterologous antigen replaces all or part of the UL7, UL38, UL45, or US13 gene.

11. The recombinant HCMV of claim 10 , wherein expression of the at least one heterologous antigen replacing all or part of the UL7, UL38, UL45, or US13 gene is driven by the UL7, UL38, UL45 , or US13 promoter.

12. The recombinant HCMV of claim 1 , further comprising an inactivating mutation in the UL128 gene or the UL130 gene.

13. The recombinant HCMV of claim 12 , wherein the recombinant HCMV comprises an inactivating mutation in the UL128 gene and the UL130 gene.

14. The recombinant HCMV of claim 1 , wherein the at least one heterologous antigen is a pathogen specific antigen or tumor antigen.

15. The recombinant HCMV of claim 1 , wherein the nucleic acid sequences encoding the recombinant HCMV genome and the at least one heterologous antigen are stable upon multiple passages through fibroblasts.

16. The recombinant HCMV of claim 1 , further comprising a second heterologous antigen.

17. The recombinant HCMV of claim 16 , wherein the first heterologous antigen replaces all or part of the UL78 gene, and wherein the second heterologous antigen replaces all or part of an HCMV gene selected from the group consisting of: UL7, UL45, and US13.

18. The recombinant HCMV of claim 17 , wherein the expression of the first heterologous antigen is driven by the UL78 promoter, and wherein the expression of the second heterologous antigen is driven by the UL7 promoter, the UL45 promoter, or the US13 promoter.

19. The recombinant HCMV of claim 1 , wherein the first heterologous antigen is a pathogen specific antigen or tumor antigen.

20. The recombinant HCMV of claim 19 , wherein the second heterologous antigen is a pathogen specific or tumor antigen that is different from the first heterologous antigen.

21. The recombinant HCMV of claim 16 , wherein the nucleic acid sequences encoding the recombinant HCMV genome and the first and second heterologous antigens are stable upon multiple passages through fibroblasts.

22. An immunogenic composition comprising the recombinant HCMV of claim 1 and a pharmaceutically acceptable carrier.

23. A method of inducing an immune response in a subject, the method comprising: administering an effective amount of the immunogenic composition of claim 22 to the subject.

24. The method of claim 23 , wherein administration of the recombinant HCMV induces and maintains a long-term effector memory T cell response to the at least one heterologous antigen.

25. An immunogenic composition comprising the recombinant HCMV of claim 16 and a pharmaceutically acceptable carrier.

26. A method of inducing an immune response in a subject, the method comprising: administering an effective amount of the immunogenic composition of claim 25 to the subject.

27. The method of claim 26 , wherein administration of the recombinant HCMV vector induces and maintains a long-term effector memory T cell response to the first and second heterologous antigens.

28. An isolated polynucleotide that encodes the recombinant HCMV vector of claim 1 .

29. An isolated cell comprising the polynucleotide of claim 28 .

30. The isolated cell of claim 29 , wherein the isolated cell is a mammalian cell.

Assignees

• Univ Oregon Health & Science

Inventors

• Frueh Klaus
• Hansen Scott G
• Nelson Jay
• Picker Louis
• Caposio Patrizia

Classifications

• A61K39/0011

  Cancer antigens · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61K39/39

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title

• C12N2710/16143

  viral genome or elements thereof as genetic vector · CPC title

• A61K2039/5254

  avirulent or attenuated · CPC title